


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7780483/publications.pdf Version: 2024-02-01



VILONC

#	Article	IF	CITATIONS
1	Stromal computational signatures predict upgrade to invasive carcinoma in mass-forming DCIS: A brief report of 44 cases. Pathology Research and Practice, 2022, 231, 153771.	1.0	3
2	Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice. , 2022, 000, 000-000.		2
3	Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer. Breast Cancer Research and Treatment, 2021, 186, 667-676.	1.1	5
4	Apocrine ductal carcinoma in situ associated with testosterone therapy in a transgender individual. Breast Journal, 2021, 27, 475-477.	0.4	7
5	Risk factors for breast cancer development by tumor characteristics among women with benign breast disease. Breast Cancer Research, 2021, 23, 34.	2.2	14
6	Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer. Breast Cancer Research, 2021, 23, 15.	2.2	3
7	How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110350.	0.8	1
8	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. BMJ Open, 2021, 11, e053397.	0.8	1
9	Papillary neoplasm of the breast – A review and update. Human Pathology Reports, 2021, 26, 300581.	0.1	1
10	Dietary Fermented Soy Extract and Oligo-Lactic Acid Alleviate Chronic Kidney Disease in Mice via Inhibition of Inflammation and Modulation of Gut Microbiota. Nutrients, 2020, 12, 2376.	1.7	22
11	Low-grade adenosquamous carcinoma of the breast: A case with pathogenic germline mutation in the BRIP1 gene. Human Pathology: Case Reports, 2020, 22, 200444.	0.2	0
12	Clinicopathologic update of calcium oxalate in breast: A 15â€year retrospective review. Breast Journal, 2020, 26, 1736-1741.	0.4	4
13	Elastin in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1272, 1-16.	0.8	16
14	Discordant <scp>HER</scp> 2 immunohistochemical expression and gene amplification in ductal carcinoma <i>inÂsitu</i> – evaluating <scp>HER</scp> 2 in synchronous <i>inâ€situ</i> and invasive carcinoma. Histopathology, 2019, 74, 358-362.	1.6	2
15	Cholesteroloma of the breast: A 10 year retrospective review of 79 cases with radiology correlation. Breast Journal, 2019, 25, 1177-1181.	0.4	5
16	Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. BMC Cancer, 2019, 19, 1036.	1.1	4
17	Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance. BMC Cancer, 2019, 19, 1085.	1.1	17
18	Pilomatricoma of the male breast. Breast Journal, 2019, 25, 1012-1013.	0.4	0

YIHON

#	Article	IF	CITATIONS
19	Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. Oncogenesis, 2019, 8, 14.	2.1	62
20	A miRNA Expression Signature in Breast Tumor Tissue Is Associated with Risk of Distant Metastasis. Cancer Research, 2019, 79, 1705-1713.	0.4	14
21	ColXî±1 is a stromal component that colocalizes with elastin in the breast tumor extracellular matrix. Journal of Pathology: Clinical Research, 2019, 5, 40-52.	1.3	3
22	A 10 year retrospective review of fine needle aspiration cytology of cystic lesions of the breast with emphasis on papillary cystic lesions. Diagnostic Cytopathology, 2019, 47, 400-403.	0.5	2
23	In reply to Lambein <i>etÂal</i> .: â€~ <scp>HER</scp> 2 protein overexpression in nonâ€amplified ductal carcinoma <i>inÂsitu</i> : quality issue or transcription mechanisms gone awry?'. Histopathology, 2019, 74, 666-666.	1.6	0
24	Symptomatic Fibroadenoma Resolves Status Post Cryoablation. Rhode Island Medical Journal (2013), 2019, 102, 49-52.	0.2	0
25	Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers. Human Pathology, 2018, 77, 11-19.	1.1	24
26	Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision. Clinical Breast Cancer, 2018, 18, e449-e454.	1.1	24
27	An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. Cancer Research, 2018, 78, 103-114.	0.4	13
28	Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e373-e379.	1.1	9
29	Relationship of histologic grade and histologic subtype with oncotype Dx recurrence scoreĺ¾ retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Research and Treatment, 2018, 168, 29-34.	1.1	32
30	Diffuse dermal angiomatosis mimicking inflammatory breast carcinoma. Breast Journal, 2018, 24, 196-198.	0.4	9
31	Cystic neutrophilic granulomatous mastitis with corynebacterium and staphylococcus mimicking breast carcinoma. Clinical Case Reports (discontinued), 2018, 6, 2208-2210.	0.2	9
32	BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1252-1256.	0.6	21
33	Evaluating agreement, histological features, and relevance of separating pleomorphic and florid lobular carcinoma in situ subtypes. Human Pathology, 2018, 78, 163-170.	1.1	7
34	Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer. British Journal of Cancer, 2018, 118, 1662-1664.	2.9	9
35	MicroRNA expression in benign breast tissue and risk of subsequent invasive breast cancer. PLoS ONE, 2018, 13, e0191814.	1.1	9
36	Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients. Human Pathology, 2017, 65, 123-132.	1.1	5

YIHON

#	Article	IF	CITATIONS
37	Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease. Breast Cancer Research and Treatment, 2017, 165, 623-631.	1.1	26
38	Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast?. Clinical Breast Cancer, 2017, 17, 127-133.	1.1	11
39	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. International Journal of Molecular Sciences, 2017, 18, 627.	1.8	15
40	Collagen type III α1 as a useful diagnostic immunohistochemical marker for fibroepithelial lesions of the breast. Human Pathology, 2016, 57, 176-181.	1.1	14
41	Clinical and Radiologic Follow-up Study for Biopsy Diagnosis of Radial Scar/Radial Sclerosing Lesion without Other Atypia. Breast Journal, 2016, 22, 637-644.	0.4	21
42	Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. BMC Cancer, 2016, 16, 274.	1.1	42
43	High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer. Clinical Breast Cancer, 2013, 13, 103-108.	1.1	27
44	Characterization of a human βVâ€ŧubulin antibody and expression of this isotype in normal and malignant human tissue. Cytoskeleton, 2012, 69, 566-576.	1.0	11
45	Combinatorial Effect of Non-Steroidal Anti-inflammatory Drugs and NF-κB Inhibitors in Ovarian Cancer Therapy. PLoS ONE, 2011, 6, e24285.	1.1	50
46	A Novel Pathway Involving Melanoma Differentiation Associated Gene-7/Interleukin-24 Mediates Nonsteroidal Anti-inflammatory Drug–Induced Apoptosis and Growth Arrest of Cancer Cells. Cancer Research, 2006, 66, 11922-11931.	0.4	54
47	NF-ÂB-mediated repression of growth arrest- and DNA-damage-inducible proteins 45 and is essential for cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13618-13623.	3.3	151
48	Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Research, 2003, 63, 2206-15.	0.4	137